About
Yamo Pharmaceuticals is developing L1-79, an oral investigational drug targeting the core social-interaction deficits in Autism Spectrum Disorder, currently advancing to Phase 3 clinical trials with FDA Fast Track designation.
Explore Yamo Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.